docetaxel anhydrous has been researched along with chir 258 in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (chir 258) | Trials (chir 258) | Recent Studies (post-2010) (chir 258) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 29 | 0 | 24 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | chir 258 (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.339 | |
| Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | 0.0808 | |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | 0.002 | |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | 0.0162 | |
| Hepatocyte growth factor receptor | Homo sapiens (human) | 0.0011 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.003 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.0134 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.0088 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.0065 | |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | 0.0075 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.0045 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0303 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.002 | |
| Serine/threonine-protein kinase TBK1 | Homo sapiens (human) | 0.06 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
1 other study(ies) available for docetaxel anhydrous and chir 258
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |